We are experiencing some temporary issues. The market data on this page are currently delayed. Please bear with us as we address this and restore your personalized lists.

U.S. Markets closed

Delcath Systems, Inc. (DCTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
2.55+0.10 (+4.08%)
At close: 3:56PM EDT
Full screen
Previous Close2.45
Open2.55
Bid0.00 x 0
Ask0.00 x 0
Day's Range2.28 - 2.55
52 Week Range2.19 - 42,000.00
Volume4,233
Avg. Volume12,272
Market Cap2.287M
Beta-1.07
PE Ratio (TTM)N/A
EPS (TTM)-151.79
Earnings DateMar 23, 2017 - Mar 24, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est16.00
Trade prices are not sourced from all markets
  • GlobeNewswire4 days ago

    Delcath Systems Announces Rights Offering and Backstop Commitment Ownership Date of August 1, 2018

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it has filed a registration statement on Form S-1 with the SEC for a rights offering for up to 28,571,429 shares of common stock at the subscription price of $1.75 per share. Under the terms of the rights offering, on August 3, 2018, Delcath expects to distribute, at no charge, 500 non-transferable subscription rights to purchase shares of its common stock to holders of record for each share of common stock held on the record date, and to holders of its warrants to purchase common stock held on the Ownership Date, as of 4:00 p.m., Eastern time, on Wednesday, August 1, 2018.

  • GlobeNewswire11 days ago

    Delcath Announces 100th Commercial CHEMOSAT Treatment Completed at Leiden University Medical Center, The Netherlands

    Delcath Systems, Inc. (DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that physicians at Leiden University Medical Center (LUMC) in the Netherlands, led by Dr. Mark C. Burgmans, completed their 100th treatment with PHP® Therapy using the company’s Hepatic CHEMOSAT® Delivery System (CHEMOSAT). Percutaneous Hepatic Perfusion (PHP) Therapy with Melphalan/HDS was developed by Delcath Systems as a targeted, whole organ therapy for the liver.

  • GlobeNewswire2 months ago

    Delcath Systems to Present at the 8th Annual LD Micro Invitational

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, today announced that it will be presenting at the 8th Annual LD Micro Invitational on Monday, June 4 at 12:00pm PST / 3:00pm EST. Jennifer K. Simpson, PhD, MSN, CRNP, President and Chief Executive Officer of Delcath Systems, will be presenting and meeting with investors. Dr. Simpson’s presentation will be webcast live on the internet and can be accessed by visiting the News and Events section of the Company’s website at www.delcath.com.

  • GlobeNewswire2 months ago

    Delcath Sponsors Looking For A Cure Ocular Melanoma Charity Event

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, is proud to sponsor A Cure In Sight and its first annual Looking for a Cure 5K charity event.  A Cure in Sight is a patient advocacy group dedicated to providing patient services for ocular melanoma patients and their families. Looking for a Cure was held in Palo Alto, CA at the Byers Eye Institute on May 20, 2018. The event raised over $15,000 to support A Cure In Sight’s efforts in research, awareness and financial support programs for ocular melanoma patients.

  • GlobeNewswire2 months ago

    Delcath’s CHEMOSAT Included in German Treatment Guidelines for Melanoma Liver Metastases

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the German Guidelines Program in Oncology (GGPO) has included treatment with Delcath’s CHEMOSAT® in the German national treatment guidelines for liver metastases from melanoma. This inclusion of treatment with CHEMOSAT is in the S3 Guidelines, which represents the highest level within the classification of the guidelines indicating that it is based on evidence and consensus within the German clinical community. The GGPO’s update was based on its evaluation of published data on treatment with CHEMOSAT as a loco-regional treatment for melanoma liver metastases.  Following this evaluation, and after soliciting additional feedback from the oncology community in Germany, treatment with CHEMOSAT was classified with Evidence Level 1B, indicating the second highest level of evidence.

  • GlobeNewswire2 months ago

    Delcath’s PHP Therapy Featured in Video Learning Session at the European Conference of Interventional Oncology 

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company’s PHP Therapy was featured in a Video Learning Session presented at the Annual Meeting of the European Conference of Interventional Oncology (ECIO). Dr. M.C. Burgmans of Leiden University Medical Center (LUMC) in the Netherlands presented the training in the main auditorium session dedicated to advances in liver cancer therapies.  Dr. Burgmans presented an overview of the Percutaneous Hepatic Perfusion (PHP) procedure, discussed the therapy’s developmental history, demonstrating how to perform the procedure, as well as outlining its potential in ocular melanoma liver metastases and intrahepatic cholangiocarcinoma, and highlighting ongoing clinical research.

  • GlobeNewswire2 months ago

    Delcath Announces First Quarter 2018 Financial Results

    NEW YORK, May 10, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces financial results for the quarter ended March ...

  • GlobeNewswire2 months ago

    Delcath Announces Initiation of Registrational Trial of Melphalan/HDS in Intrahepatic Cholangiocarcinoma

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the Company has initiated its pivotal trial of Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System (Melphalan/HDS) to treat patients with intrahepatic cholangiocarcinoma (ICC). The trial, entitled A Randomized, Controlled Study to Compare the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment Given Sequentially Following Cisplatin/Gemcitabine versus Cisplatin/Gemcitabine (Standard of Care) in Patients with Intrahepatic Cholangiocarcinoma, (the ALIGN Trial) will seek to enroll approximately 295 ICC patients at approximately 40 clinical sites in the U.S. and Europe.

  • GlobeNewswire3 months ago

    Delcath to Present at the RHK Capital 2018 Disruptive Growth and Healthcare Conference

    NEW YORK, May 04, 2018-- Delcath Systems, Inc., an interventional oncology Company focused on the treatment of primary and metastatic liver cancers, announces that Jennifer K. Simpson, Ph.D., MSN, CRNP, ...

  • GlobeNewswire3 months ago

    Delcath Announces Another DSMB Recommendation for Phase 3 Focus Trial

    Delcath Systems, Inc. (DCTHD), an interventional oncology company focused on the treatment of primary and metastatic liver cancers, announces that the independent Data Safety Monitoring Board (DSMB) of the Phase 3 FOCUS clinical trial for Patients with Hepatic Dominant Ocular Melanoma has completed another review of safety data for treated patients in the trial. The FOCUS Trial is evaluating the efficacy, safety and pharmacokinetics of Melphalan/HDS versus best alternative standard of care in 240 patients with metastatic ocular melanoma (OM).